Excellent find qdelfan. Thanks.
Barber says Vertex didn’t make an announcement because “formulation work and regulatory discussions have been ongoing” since the deal was struck, and it “wanted to communicate about the VX-210 program when we had further clarity on the development program and next steps.”
Vertex expects to provide those details when it starts the next trial of the drug later this year, he says.
I think you can extrapolate data from the language they used. Based on their news release ALO-02 is only "abuse deterrent formulation." Definition of deterrent is "a thing that discourages or is intended to discourage someone from doing something."
However, 181 has a " unique molecular design of the polymer drug conjugate (that) also prevents conversion of NKTR-181 into a rapid-acting abusable form of an opioid."
A world of difference between "discourage" and "prevent."
"you didnt buy low and sell high. Thats CG's fault??."
When investors find out about a stock, as part of their due diligence they look at what the CEO has said and is saying about his/her company and its products. Based on that information a person may decide a stock has a good chance to appreciate. In the biotech world it is very difficult to know when a stock is low or high. Biotech stock valuation is not like valuing a stock in an industry that has a stable sales and earnings -- it is based on the value of what is in the pipeline.
Hope this helps.
Whether he is badmouthing NKTR stock of pretending he is buying I always give his posts and also his other identity posts a thumb down because this guy is either a juvenile, imbecile or idiot. However, I don't waste time directly responding to his idiotic posts. It is a waste of time and by responding to him, whether positive or negative!, he gets a rise.
corona, yo funny man. I like that. hehehe
Give him a raise? I am assuming you are not kidding. If so please give me a break. I am sitting here with a big loss and you want to give this incompetent person a raise?
Although I am no fan of the FDA, the problem stems with Chris' incompetency. He should have asked more pointed questions as to what they wanted and required rather than having fuzzy meetings during which he did not nail the regulators as to the specifics they needed for approval.
The reason for employee count having gone down is due to the discontinuation of Incivek. The company wisely laid off about 360 employees that were connected to that drug.
Does anyone know what the Gardner brothers are saying about 3 d printer stocks now? Based on their recommendations I invested in xone and DDD and have a lot of losses. Last year I complained in a Motley Fools post and I got a response that I should be a "long term investor" implying in the long term these stocks will rebound to their former glory. I was so #$%$ that I did not even bother to respond by asking what their definition of long term was.
I guess it amounts to live and learn -- don't buy a stock that has gone up and up and up just because some idiots from wall street keep hyping it.